Orchard Therapeutics opens US operations in Foster City, California
Will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products.
Orchard Therapeutics, a UK-based biotechnology company, has announced the opening of its US operations in Foster City, California.
Orchard is developing a global platform of ex-vivo autologous gene therapies in serious and life-threatening orphan diseases. In the US, Orchard has collaborations with the University of California Los Angeles and Boston Children’s Hospital, and with leading manufacturing partners specialized in gene and cell therapy.
Foster City will serve as headquarters for the company’s North American subsidiary, Orchard Therapeutics North America, and will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products.
Dr Stewart Craig, Orchard’s Chief Manufacturing Officer, commented, “We are building a world-class team of experts in the development, manufacture, testing and delivery of cell-based gene therapy products. This facility represents a next key step in establishing a central technical capability to support the global clinical development and commercialization of Orchard’s products”.
Orchard’s lead program in severe combined immunodeficiency due to adenosine deaminase deficiency is an advanced clinical development, with a total of 39 patients treated as of September 2016.
Dr Alexander Pasteur, interim CEO, added: “Our goal is to become a category leader in ex-vivo autologous gene therapy for rare conditions. The opening of our US operations in California is a key step in building the global platform that can deliver Orchard’s transformative therapies to patients wherever they are.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance